IMS Capital Management reduced its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 50.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,125 shares of the medical research company’s stock after selling 2,125 shares during the quarter. IMS Capital Management’s holdings in Edwards Lifesciences were worth $467,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Ledyard National Bank grew its stake in Edwards Lifesciences by 0.5% during the 2nd quarter. Ledyard National Bank now owns 9,178 shares of the medical research company’s stock worth $1,696,000 after buying an additional 50 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its position in Edwards Lifesciences by 1.8% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 2,880 shares of the medical research company’s stock worth $532,000 after acquiring an additional 50 shares during the period. Pitcairn Co. boosted its position in Edwards Lifesciences by 0.3% during the 2nd quarter. Pitcairn Co. now owns 18,756 shares of the medical research company’s stock worth $3,465,000 after acquiring an additional 51 shares during the period. Tarbox Family Office Inc. boosted its position in Edwards Lifesciences by 48.7% during the 2nd quarter. Tarbox Family Office Inc. now owns 177 shares of the medical research company’s stock worth $33,000 after acquiring an additional 58 shares during the period. Finally, Advisory Services Network LLC boosted its position in Edwards Lifesciences by 0.4% during the 2nd quarter. Advisory Services Network LLC now owns 14,932 shares of the medical research company’s stock worth $2,759,000 after acquiring an additional 59 shares during the period. Hedge funds and other institutional investors own 81.53% of the company’s stock.

In other news, VP Catherine M. Szyman sold 372 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $214.53, for a total transaction of $79,805.16. Following the completion of the sale, the vice president now directly owns 18,010 shares of the company’s stock, valued at $3,863,685.30. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Catherine M. Szyman sold 1,152 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $191.70, for a total value of $220,838.40. Following the sale, the vice president now directly owns 19,162 shares of the company’s stock, valued at $3,673,355.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 155,822 shares of company stock valued at $33,641,784. Insiders own 1.63% of the company’s stock.

A number of brokerages have issued reports on EW. Wells Fargo & Co boosted their price target on Edwards Lifesciences from $220.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, September 6th. Credit Suisse Group boosted their price target on Edwards Lifesciences from $221.00 to $226.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $232.00 price target for the company in a research report on Thursday, July 25th. BMO Capital Markets boosted their price target on Edwards Lifesciences from $204.00 to $224.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Finally, Piper Jaffray Companies began coverage on Edwards Lifesciences in a research report on Monday, September 23rd. They set an “overweight” rating and a $240.00 price target for the company. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company’s stock. Edwards Lifesciences has an average rating of “Buy” and a consensus target price of $208.42.

Shares of Edwards Lifesciences stock traded up $6.78 during trading on Wednesday, hitting $224.81. The stock had a trading volume of 1,007,824 shares, compared to its average volume of 1,245,285. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.38 and a quick ratio of 2.48. The firm has a market cap of $47.71 billion, a P/E ratio of 47.83, a PEG ratio of 2.89 and a beta of 0.84. The business has a fifty day moving average of $219.73 and a two-hundred day moving average of $196.94. Edwards Lifesciences Corp has a fifty-two week low of $136.44 and a fifty-two week high of $229.97.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.33 by $0.05. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.04 billion. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The company’s revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.24 earnings per share. As a group, research analysts forecast that Edwards Lifesciences Corp will post 5.34 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: Stock Symbols, CUSIP and Other Stock Identifiers

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.